It’s a busy day for U.K.-based Tenpoint Therapeutics, which has secured U.S. Food and Drug Administration (FDA) approval for YUVEZZI, a combination eye drop for the treatment of presbyopia, while raising $235 million to support its commercial rollout at the same time.
PulseSight Therapeutics SAS was launched on Wednesday, backed by seed financing from Pureos Bioventures and ND Capital. The company introduces a disruptive delivery platform in ophthalmology biotech, focusing on the development of non-viral gene therapies coupled with minimally-invasive delivery technology.
ETH Zurich researchers have developed a gene switch that triggers insulin release in designer cells by playing music.